Why the study?
Does thrombospondin-1 induce platelet activation through CD36-dependent inhibition of the cAMP/PKA signaling cascade?
Population
Platelets (preclinical model)
Comparison
Thrombospondin-1 (TSP-1) and CD36 binding peptide vs Control, CD36 blocking antibody, or Src kinase…
Design
Preclinical
Authors
Loading...
TSP-1-CD36 signaling modulates platelet cAMP in animal models; leaves open whether this pathway offers a viable antithrombotic target in humans.
Does thrombospondin-1 induce platelet activation through CD36-dependent inhibition of the cAMP/PKA signaling cascade?
Thrombospondin-1 promotes platelet aggregation by inhibiting the cAMP-PKA signaling pathway through a CD36-dependent mechanism, revealing a novel regulatory pathway in platelet activation.
Roberts et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: